1. [Tick-borne encephalitis with fulminant course and lethal outcome in patients after plural vaccination].
- Author
-
Pogodina VV, Levina LS, Skrynnik SM, Travina NS, Karan' LS, Kolesnikova NM, Karmysheva VIa, Gerasimov SG, Malenko GV, and Perminov LV
- Subjects
- Animals, Antiviral Agents administration & dosage, Brain Edema chemically induced, Brain Edema immunology, Brain Edema virology, Fatal Outcome, Female, Humans, Immunoglobulins administration & dosage, Male, Respiratory Distress Syndrome chemically induced, Respiratory Distress Syndrome immunology, Respiratory Distress Syndrome virology, Antiviral Agents adverse effects, Encephalitis Viruses, Tick-Borne, Encephalitis, Tick-Borne drug therapy, Encephalitis, Tick-Borne immunology, Encephalitis, Tick-Borne prevention & control, Immunoglobulins adverse effects, Vaccination, Viral Vaccines administration & dosage
- Abstract
In the Kurgan region, the Siberian subtype of the tick-borne encephalitis virus (TBEV) is dominant. The vaccines prepared from Far-Eastern TBEV subtype are used in this area. Among TBE patients in 2007-2011, 23.79% were vaccinated according to complete or incomplete course. 76.9% of persons were vaccinated with Encevir vaccine, Tomsk. An unusual focal form of TBE with fulminant disease with lethal outcome was developed in a patient who was vaccinated 6 times with heterotype vaccines produced using the strains of the Far-Eastern TBE subtype. Inoculation of immunoglobulin in hospital produced aggravation of clinical symptoms, development of convulsions, brain oedema, and respiratory distress syndrome. The disease continues only 55 hours from first symptoms to fatal outcome. Siberian subtype of TBEV was isolated from patient spinal cord (Kurgan-118-2010 strain). Possible mechanisms of this disease are discussed.
- Published
- 2013